Actively Recruiting
Long-Term Safety and Efficacy Follow-Up of Lentiviral-Based Gene-Edited Immune Cell Therapy in Patients
Led by Pell Bio-Med Technology Co., Ltd. · Updated on 2026-10-09
49
Participants Needed
5
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates the long-term safety and efficacy of lentiviral-based gene-edited immune cell therapy in patients who have previously received this treatment. The study responds to health authority guidelines recommending a 15-year follow-up to monitor delayed adverse events after gene therapy. It focuses on patients treated with therapies manufactured by Pell Bio-Med Technology Co. Ltd. and aims to collect extended safety and effectiveness data. Participants enroll in this observational study after completing or withdrawing early from a prior gene-edited immune cell therapy protocol. Enrollment can occur immediately after the previous treatment or at any time within 15 years following the last infusion. Some participants may join other Pell gene-edited immune cell therapy studies while remaining inactive in this follow-up study. Throughout the 15-year follow-up, researchers monitor for delayed adverse events potentially related to previous therapy. Assessments include testing for replication-competent lentivirus and tracking the persistence of gene-edited immune cells in blood using qPCR and flow cytometry. This long-term monitoring helps evaluate both safety and sustained efficacy, with the entire participation lasting up to 15 years.
CONDITIONS
Brief Title
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Research Team
T
T. Hsun Lin, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here